TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Cetera Investment Advisers

Cetera Investment Advisers lessened its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 21.6% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,705 shares of the company’s stock after selling 2,401 shares during the quarter. Cetera Investment Advisers’ holdings in TransMedics Group were worth $1,311,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Fidelis Capital Partners LLC acquired a new stake in shares of TransMedics Group in the first quarter worth $35,000. International Assets Investment Management LLC acquired a new stake in TransMedics Group in the 2nd quarter valued at $47,000. J.Safra Asset Management Corp raised its position in TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares during the period. Signaturefd LLC lifted its stake in shares of TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares in the last quarter. Finally, Amalgamated Bank boosted its position in shares of TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after buying an additional 70 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TMDX. Needham & Company LLC assumed coverage on TransMedics Group in a research report on Wednesday, August 21st. They set a “buy” rating and a $208.00 price target on the stock. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price objective on shares of TransMedics Group in a report on Monday, October 7th. Morgan Stanley raised their target price on TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Oppenheimer boosted their price target on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, August 1st. Finally, Canaccord Genuity Group increased their price target on TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $174.30.

TransMedics Group Stock Performance

TMDX stock opened at $131.84 on Wednesday. The company has a 50-day simple moving average of $154.43 and a 200 day simple moving average of $137.60. The company has a market capitalization of $4.34 billion, a P/E ratio of -387.76 and a beta of 1.99. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $177.37. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The business had revenue of $114.30 million during the quarter, compared to analyst estimates of $98.84 million. During the same period last year, the company posted ($0.03) EPS. The company’s revenue was up 117.7% compared to the same quarter last year. Sell-side analysts predict that TransMedics Group, Inc. will post 1.22 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $9,457,269.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Nicholas Corcoran sold 10,000 shares of TransMedics Group stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares in the company, valued at $3,714,902.10. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 55,580 shares of company stock valued at $8,837,283. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.